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Abstract
 
The Shiga toxigenic 
 
Escherichia coli
 
 (STEC) O113:H21 strain 98NK2, which was responsible
for an outbreak of hemolytic uremic syndrome, secretes a highly potent and lethal subtilase cyto-
toxin that is unrelated to any bacterial toxin described to date. It is the prototype of a new family
of AB
 
5
 
 toxins, comprising a single 35-kilodalton (kD) A subunit and a pentamer of 13-kD B
subunits. The A subunit is a subtilase-like serine protease distantly related to the BA_2875 gene
product of 
 
Bacillus anthracis
 
. The B subunit is related to a putative exported protein from 
 
Yersinia
pestis
 
, and binds to a mimic of the ganglioside GM2. Subtilase cytotoxin is encoded by two
closely linked, cotranscribed genes (
 
subA
 
 and 
 
subB
 
), which, in strain 98NK2, are located on a
large, conjugative virulence plasmid. Homologues of the genes are present in 32 out of 68
other STEC strains tested. Intraperitoneal injection of purified subtilase cytotoxin was fatal for
mice and resulted in extensive microvascular thrombosis, as well as necrosis in the brain, kid-
neys, and liver. Oral challenge of mice with 
 
E. coli
 
 K-12–expressing cloned 
 
subA
 
 and 
 
subB
 
 resulted
in dramatic weight loss. These findings suggest that the toxin may contribute to the pathogen-
esis of human disease.
Key words: subtilase • enterohemorrhagic 
 
E. coli
 
 • serine protease • hemolytic uremic syndrome • 
microvascular thrombosis
 
Introduction
 
AB
 
5
 
 toxins produced by pathogenic bacteria comprise an A
subunit with enzymic activity and a B subunit pentamer
responsible for interaction with glycolipid receptors on target
eukaryotic cells (1). The three AB
 
5
 
 toxin families recog-
nized to date are the Shiga toxin (Stx), cholera toxin and
the related 
 
Escherichia coli
 
 heat labile enterotoxins, and per-
tussis toxin (Ptx). In each case, they are key virulence determi-
nants of the bacteria that produce them (Shiga toxigenic 
 
E.
coli
 
 [STEC] and 
 
Shigella dysenteriae
 
, 
 
Vibrio cholerae
 
, and entero-
toxigenic 
 
E. coli
 
, and 
 
Bordetella pertussis
 
, respectively). Col-
lectively, these pathogens cause massive global morbidity
and mortality, accounting for millions of deaths each year,
particularly amongst children in developing countries. The
AB
 
5
 
 toxins exert their catastrophic effects by a two-step
process involving B subunit–mediated entry of their respective
target cells, followed by A subunit–dependent inhibition
or corruption of essential host functions. The A subunits
of Stx have RNA-
 
N
 
-glycosidase activity and cleave 28S
rRNA, thereby inhibiting host protein synthesis. The A
subunits of cholera toxin/labile enterotoxin and Ptx are
ADP ribosylases that modify distinct host G proteins, resulting
in alteration of intracellular cAMP levels and disregulation
of ion transport mechanisms (1).
STEC are an important cause of gastrointestinal disease
in humans, particularly because these infections may result
in life-threatening sequelae such as the hemolytic uremic
syndrome (HUS; 2, 3). STEC are a very diverse group
comprising 
 
 
 
200 
 
E. coli
 
 O:H serotypes (2), but epidemio-
logical data indicate that not all of these are highly virulent
for humans. Thus, although Stx is generally considered to
be a sine qua non of virulence, additional STEC properties
undoubtedly contribute to the pathogenic process (2, 3).
Moreover, there has been a finding of strains of 
 
E. coli
 
O157:H7 and O157:H
 
 
 
 that do not produce Stx being associ-
ated with cases of human gastrointestinal disease, including
 
Address correspondence to James C. Paton, School of Molecular
and Biomedical Science, University of Adelaide, South Australia,
5005, Australia. Phone: 61-8-83035929; Fax: 61-8-83033262; email:
james.paton@adelaide.edu.au
 
Abbreviations used in this paper:
 
 aa, amino acid; CHO, Chinese hamster
ovary; HUS, hemolytic uremic syndrome; IPTG, isopropyl-
 
 
 
-
 
d
 
-thioga-
lactopyranoside; LB, Luria-Bertani; nt, nucleotide; Ni-NTA, nickel nitrilotri-
acetic acid; ORF, open reading frame; Ptx, pertussis toxin; STEC, Shiga
toxigenic 
 
Escherichia coli
 
; Stx, Shiga toxin. 
E. coli
 
 Subtilase Cytotoxin
 
36
HUS (4). Here, we demonstrate that certain STEC strains
produce a hitherto unknown yet highly lethal AB
 
5
 
 toxin.
We have characterized the prototype of this new toxin
family, which was secreted by a highly virulent O113:H21
STEC strain responsible for an outbreak of HUS.
 
Materials and Methods
 
Bacterial Strains, Plasmids, and Oligonucleotides. 
 
Bacterial
strains, plasmids, and oligonucleotides used in this work are listed
in Tables I and II. The O113:H21 STEC strain 98NK2 was iso-
lated from a patient with HUS at the Women’s and Children’s
Hospital, South Australia, as described previously (5). Other clin-
ical STEC strains used in this work were also isolated at the
Women’s and Children’s Hospital. All 
 
E. coli
 
 strains were rou-
tinely grown in Luria-Bertani (LB) medium (6) with or without
1.5% bacto-agar. Where appropriate, ampicillin or kanamycin
were added to growth media at a concentration of 50 
 
 
 
g/ml.
 
Toxin Adsorption/Neutralization with Receptor Mimic Bacteria.
E. coli
 
 CWG308:pJCP-Gb
 
3
 
, expressing a modified lipopolysac-
charide that mimics the Stx receptor Gb
 
3
 
 (7) was grown over-
night in LB broth supplemented with 20 
 
 
 
g/ml isopropyl-
 
 
 
-
 
d
 
-
thiogalactopyranoside (IPTG), and 50 
 
 
 
g/ml kanamycin. Cells
were harvested by centrifugation, washed, and resuspended in
PBS at a density of 10
 
9
 
 CFU/ml. 250 
 
 
 
l of 98NK2 culture super-
natant was incubated with 500 
 
 
 
l of this suspension for 1 h at
37
 
 
 
C with gentle agitation. The mixture was centrifuged, filter
sterilized, and assayed for cytotoxicity. The same procedure was
also used to compare toxin neutralization using derivatives of 
 
E.
coli
 
 CWG308 expressing mimics of Gb
 
4
 
, lactoneotetraose, and
GM
 
2
 
 (reference 8 and unpublished data). Neutralization of cyto-
toxicity (%) was calculated as described previously (7).
 
Cell Culture and Cytotoxicity Assays. 
 
All tissue culture media
and reagents were obtained from Life Technologies. Vero (Afri-
can green monkey kidney) cells were grown at 37
 
 
 
C in DMEM
supplemented with 10% heat inactivated FCS, 50 IU penicillin,
and 50 
 
 
 
g/ml streptomycin, unless otherwise indicated. Chinese
hamster ovary (CHO) cells were grown in Ham’s F12 medium,
whereas human colonic epithelial (Hct-8) cells were grown in
RPMI 1640 medium. For cytotoxicity assays, cells were seeded
into 96-well flat-bottom trays and incubated overnight at 37
 
 
 
C
until confluent. Confluent monolayers were washed twice with
PBS, treated with 50 
 
 
 
l of filter-sterilized toxin extracts that had
been serially diluted in the appropriate tissue culture medium
(without FCS), and incubated at 37
 
 
 
C for 30 min. After incuba-
tion, 150 
 
 
 
l of medium supplemented with 2% FCS was added
per well. Cytotoxicity was assessed microscopically after 3 d of
incubation at 37
 
 
 
C. The toxin titer was defined as the reciprocal
of the maximum dilution producing a cytopathic effect on at least
50% of the cells in each well (CD
 
50
 
/ml).
 
Manipulation and Analysis of DNA. 
 
Recombinant DNA ex-
periments were approved by the Office of the Gene Technology
Regulator (Australia) and were performed under PC2 level con-
tainment. Routine DNA manipulations (restriction digestion,
agarose gel electrophoresis, ligation, transformation of 
 
E. coli
 
,
Southern hybridization analysis, etc.) were performed essentially
as described previously (6). For DNA sequencing, a plasmid
DNA template was purified using a QIAPrep Spin miniprep kit
(QIAGEN). The sequence of both strands was determined using
dye-terminator chemistry and either universal M13 sequencing
primers or custom-made oligonucleotide primers on an auto-
mated DNA sequencer (model 3700; Applied Biosystems).
 
Subcloning of subAB. 
 
The 
 
subA
 
, 
 
subB
 
, or both 
 
subA
 
 and 
 
subB
 
(
 
subAB
 
) open reading frames (ORFs) were amplified from
98NK2 genomic DNA by PCR using primer pairs SubAF/
SubAR, SubBF/SubBR, and SubAF/SubBR, respectively, using
the Expand™ High Fidelity PCR system (Roche Molecular Di-
agnostics), according to the manufacturer’s instructions. The pu-
rified PCR products were blunt cloned into SmaI-digested
pK184, and transformed into 
 
E. coli
 
 JM109. Recombinant plas-
mids were extracted from transformants and confirmed by se-
quence analysis. In all cases, the inserts were in the same orienta-
tion as the vector 
 
lac
 
 promoter.
 
Preparation of Antisera to SubA and SubB. 
 
To raise specific
antisera, we first purified SubA and SubB using a QIAexpress kit
(QIAGEN). The 
 
subA
 
 and 
 
subB
 
 ORFs, without the 5
 
 
 
 signal
peptide-encoding regions, were amplified by high fidelity PCR
using 98NK2 genomic DNA template and primer pairs pQE-
subAF/pQEsubAR and pQEsubBF/pQEsubBR, respectively.
Purified PCR products were digested with BamHI–SacI or
SphI–SacI, respectively, ligated with similarly digested pQE30,
and transformed into 
 
E. coli
 
 M15. Correct insertion of the genes
into the vector, such that the recombinant plasmids encode de-
rivatives of SubA and SubB with His
 
6
 
 tags at their NH
 
2
 
 termini,
was confirmed by sequence analysis. For purification of His
 
6
 
-
fusion proteins, transformants were grown in 1 L of LB supple-
mented with 50 
 
 
 
g/ml ampicillin and, when the culture reached
an A
 
600
 
 of 0.5, the culture was induced with 2 mM IPTG and in-
cubated for an additional 3 h. Cells were harvested by centrifuga-
tion, resuspended in 24 ml buffer A (6 M guanidine-HCl, 0.1 M
NaH
 
2
 
PO
 
4
 
, 10 mM Tris, pH 8.0), and stirred at room tempera-
ture for 1 h. Cell debris was removed by centrifugation at 10,000
 
g
 
 for 25 min at 4
 
 
 
C. The supernatant was loaded (at a rate of 15
ml/h) onto a 2 ml column of nickel nitrilotriacetic acid (Ni-
NTA) resin (ProBond; Invitrogen), which had been preequili-
brated with 20 ml buffer A supplemented with 0.5 M NaCl and
15 mM imidazole. The column was washed with 40 ml buffer A,
followed by 20 ml buffer B (8 M urea, 0.1 M NaH
 
2
 
PO
 
4
 
, 10 mM
Tris, pH 8.0), and 16 ml buffer C (8 M urea, 0.1 M NaH
 
2
 
PO
 
4
 
,
10 mM Tris, pH 6.3) supplemented with 0.25 M NaCl and 5
 
Table I.
 
Bacterial Strains and Plasmids
 
Bacterial strain
or plasmid Relevant characteristics Ref. or source
 
E. coli
 
98NK2 O113:H21
Stx2-producing STEC
5
JM109 K-12 cloning host 32
M15 expression host
for pQE vectors
QIAGEN
Tuner™(DE3) expression host
for pET vectors
Novagen
DH5
 
 
 
SR
 
streptomycin-resistant
DH5
 
 
 
33
Plasmids
pK184 34
pQE30 QIAGEN
pET-23(
 
 
 
) Novagen 
Paton et al.
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mM imidazole. The fusion proteins were eluted with a 30-ml
gradient of 0–500 mM imidazole in buffer C, and 3-ml fractions
were collected and analyzed by SDS-PAGE. Peak fractions were
pooled, and the denatured SubA and SubB were refolded by dial-
ysis against 100 ml of buffer B to which 1 L of PBS was added
dropwise at a rate of 60 ml/h. This was followed by dialysis
against two changes of PBS. The purified SubA and SubB were
 
 
 
95% pure, as judged by SDS-PAGE after staining with Coo-
massie brilliant blue R250.
BALB/C mice were immunized by intraperitoneal injection of
three 10-
 
 
 
g doses of purified SubA or SubB in 0.2 ml PBS con-
taining 5 
 
 
 
g of alum adjuvant (Imjectalum; Pierce Chemical Co.)
at 2-wk intervals. Mice were exsanguinated by cardiac puncture
1 wk after the third immunization, and pooled antisera were
stored in aliquots at 
 
 
 
15
 
 
 
C.
 
Western Blot Analysis. 
 
Crude lysates or culture supernatants
of 
 
E. coli
 
 strains, or purified proteins were separated by SDS-
PAGE (10), and antigens were electrophoretically transferred
onto nitrocellulose filters (11). Filters were probed with poly-
clonal mouse anti-SubA or anti-SubB sera (used at a dilution of
1:5,000), or monoclonal antibody to His
 
6
 
 (QIAGEN), followed
by goat anti–mouse IgG conjugated to alkaline phosphatase (Bio-
Rad Laboratories). Labeled bands were visualized using a chro-
mogenic nitro-blue tetrazolium/X-phosphate substrate system
(Roche Molecular Diagnostics).
 
Site-directed Mutagenesis of subA. 
 
A derivative of JM109:
pK184
 
subAB
 
 with a point mutation such that the predicted active
site serine residue (S
 
271
 
) in SubA was altered to alanine was con-
structed by overlap extension PCR mutagenesis. This involved
high fidelity PCR amplification of pK184
 
subAB
 
 DNA using
primer pairs SubAF/SubOLR and SubOLF/SubBR. This gener-
ates two fragments with the necessary mutation in codon 271 of
SubA incorporated into the overlapping region by the SubOLR
and SubOLF primers. The two separate PCR products were pu-
rified and mixed together, and the complete 
 
subAB
 
 region was
reamplified using primer pair SubAF/SubBR. The resultant PCR
product was blunt-cloned into SmaI-digested pK184, and trans-
formed into 
 
E. coli
 
 JM109. Recombinant plasmids were purified
from the resultant transformants and subjected to sequence analy-
sis to confirm that the mutation had been introduced, and that
the modified 
 
subAB
 
 operon was inserted in the vector in the
same orientation as in pK184
 
subAB
 
. This construct was desig-
nated pK184
 
subA
 
A271
 
B
 
.
 
Construction of subA and subB Deletion Derivatives of STEC
98NK2. 
 
Nonpolar 
 
subA
 
 and 
 
subB
 
 deletion mutants of STEC
98NK2 were constructed using the 
 
 
 
 red recombinase system
(12). This involved high fidelity PCR amplification of the kana-
mycin resistance cartridge in pKD4 using primer pairs Sub-
AmutF/SubAmutR and SubBmutF/SubBmutR, incorporating
the direct repeated FLP recognition target common priming site
 
Table II.
 
Oligonucleotides
Name Sequence (5 –3 )
SubAF GTACGGACTAACAGGGAACTG
SubAR ATCGTCATATGCACCTCCG
SubBF GTAGATAAAGTGACAGAAGGG
SubBR GCAAAAGCCTTCGTGTAGTC
SubOLF GGTAGCGGAACGGCAGAAGCAACAGCTATAG
SubOLR AGCTGTTGCTTCTGCCGTTCCGCTACCAGTCC
SubAmutF TACCCCAGTGGTCGTATCTGTTGTTGATTCCGGAGTGGCAGTGTAGGCTGGAGCTGCTTC
SubAmutR TGTCACTTTATCTACAAGTGAAGGGTATTTATCTGCAGACCATATGAATATCCTCCTTAG
SubBmutF TGTCTATCCCTTAATCCAGCTATGGCTGAGTGGACTGGTGGTGTAGGCTGGAGCTGCTTC
SubBmutR ATTCTGTCGATGTGGTGCAGGTTGATAACCCAACAAGAGCACATATGAATATCCTCCTTAG
pQEsub CCCTGGGGATCCGATGCAATTGGTCTGACAGa
pQEsub GTTCGAGCTCACTCATCCTTCCCTGACGb
pQEsub GGTGGCATGCGGGGGATGGCATGTTTTCAGc
pQEsub CTTAGAGCTCCTTTTTCCTGTCAGGACCb
pETsubAF TTGTAAGGATCCGGAGGAGCTTATGCTTAAGa
pETBR GATTATCTCGAGTGAGTTCTTTTTCCTGTCAGGd
RTsubAF CGAATGTTTTTCTTGCTCCAG
RTsubAR ACACTGCTGACAGGATGATAAG
RTsubBF GTTTTCAGGCGTTGTTATTACC
RTsubBR CACAAAAGGTGGATACGTCC
RTsubABF GCAGATAAATACCCTTCACTTG
RTsubABR ATCACCAGTCCACTCAGCC
aRestriction site: BamHI.
bRestriction site: SacI.
cRestriction site: SphI.
dRestriction site: XhoI.E. coli Subtilase Cytotoxin 38
and sequences derived from the 5  and 3  ends of the subA or
subB genes, respectively. The resultant linear fragments were
electroporated into 98NK2 carrying the temperature-sensitive
plasmid pKD46, which encodes the   recombinase. Allelic re-
placement mutants were selected on LB-kanamycin plates at
37 C. Replacement of nucleotide (nt) 169–908 of the subA
coding sequence or nt 83–352 of subB with the kanamycin resis-
tance cartridge was confirmed by PCR and sequence analysis of
the mutants, which were designated 98NK2 subA and 98NK2
 subB, respectively.
RNA Extraction.  RNA was extracted from log-phase LB
cultures using TRIzol reagent, according to the manufacturer’s
instructions (Life Technologies). RNA was precipitated in 1/10
volume of sodium acetate, pH 4.8, and 2 volumes of 100% etha-
nol at  80 C overnight. RNA was pelleted by centrifugation at
12,000 g for 30 min at 4 C, washed in 70% ethanol, and resus-
pended in nuclease-free water. RNasein ribonuclease inhibitor
(Promega) was added to the samples. Contaminating DNA was
digested with RQ1 RNase-free DNase, followed by DNase stop
solution, according to the manufacturer’s instructions (Promega).
Real-Time RT-PCR.  The comparative levels of subA, subB,
and subAB transcripts were determined using quantitative real-
time RT-PCR, using primer pairs RTsubAF/RTsubAR, RT-
subBF/RTsubBR, and RTsubABF/RTsubABR, respectively.
These direct amplifications of 220-bp, 238-bp, and 232-bp
fragments were within subA, within subB, or spanning subA and
subB, respectively. RT-PCR was performed using the one-step
access RT-PCR system (Promega) according to the manufac-
turer’s instructions. Each reaction was performed in a final vol-
ume of 20  l, containing 20 nmol of each oligonucleotide, and
a 1/20,000 dilution of Sybr green I nucleic acid stain (Molecu-
lar Probes). The quantitative RT-PCR was performed on a cy-
cler (Rotorgene model RG-2000; Corbett Research) and in-
cluded the following steps: 45 min of reverse transcription at
48 C, followed by 2 min denaturation at 94 C, and 40 cycles of
amplification using 94 C for 30 s, 56 C for 30 s, and 72 C for
45 s.
Copurification of SubAB.  To purify the SubAB holotoxin,
the complete subAB coding region was amplified by high fidelity
PCR using 98NK2 DNA template and the primer pair pET-
subAF/pETsubBR. The resultant PCR product was digested
with BamHI and XhoI, ligated with similarly digested pET-
23( ), and transformed into E. coli Tuner™(DE3). This resulted
in IPTG-dependent production of both the SubA and SubB pro-
teins (including their respective signal peptides), but with a His6
tag fused to the COOH terminus of SubB. Correct insertion of
the genes into the vector was confirmed by sequence analysis.
Cells were grown in 1 L of LB supplemented with 50  g/ml
ampicillin and, when the culture reached an A600 of 0.5, the cul-
ture was induced with 5 mM IPTG and incubated for an addi-
tional 3 h. Cells were harvested by centrifugation, resuspended in
20 ml of loading buffer (50 mM sodium phosphate, 300 mM
NaCl, pH 8.0), and lysed in a French pressure cell. Cell debris
was removed by centrifugation at 100,000 g for 1 h at 4 C. The
supernatant was loaded onto a 2-ml column of Ni-NTA resin
that had been preequilibrated with 20 ml of loading buffer. The
column was washed with 40 ml wash buffer (50 mM sodium
phosphate, 300 mM NaCl, 10% glycerol, pH 6.0). Bound pro-
teins were eluted with a 30-ml gradient of 0–500 mM imidazole
in wash buffer, and 3-ml fractions were collected and analyzed by
SDS-PAGE.
Cross-linking of SubAB.  Purified SubAB was treated with
0.5% formaldehyde for 60 min at room temperature and heated
at 60 C for 10 min before SDS-PAGE analysis to determine the
size of the holotoxin. Purified E. coli heat labile enterotoxin (un-
published data), which is known to have AB5 stoichiometry, was
treated and analyzed in parallel.
Immunofluorescence.  Vero cells were grown on glass coverslips
in 24-well tissue culture plates and treated with or without 1  g/
ml of purified SubAB. After 1 or 48 h, cells were fixed with 4%
formaldehyde in PBS for 10 min, and in some cases permeabi-
lized with 0.1% Triton X-100. Coverslips were washed in PBS
and blocked with 20% FCS in PBS for 1 h at 37 C. They were
treated with either anti-SubA, anti-SubB, or nonimmune mouse
serum (diluted 1:800 in PBS/10% FCS) for 2 h at 37 C. After
three washes with PBS, the coverslips were reacted with goat
anti–mouse IgG–ALX488 conjugate (Molecular Probes), diluted
1:250 in PBS/10% FCS, for 30 min at 37 C. The coverslips were
washed three times with PBS, twice with water, dried, and
mounted on glass slides using 3  l of Mowiol solution with an-
tibleach. Slides were examined with a microscope (model IMT-2;
Olympus) equipped with epifluorescence optics, using a 60  oil-
immersion apochromatic objective.
Distribution of subAB.  Crude lysates of STEC strains were
subjected to PCR amplification using primer pair RTsubABF/
RTsubABR. Alternatively, HindIII digests of genomic DNA pu-
rified from the STEC strains were transferred to nylon mem-
branes and probed at high stringency with a digoxigenin-labeled
subAB DNA fragment obtained by PCR amplification of
pK184subAB using primer pair subAF/SubBR.
In Vivo Studies.  Animal experimentation was conducted in
accordance with the Australian Code of Practice for the Care and
Use of Animals for Scientific Purposes, and was approved by the
Animal Ethics Committee of the University of Adelaide. Groups
of eight 5–6-wk-old BALB/C mice, each weighing  17–19 g,
were given oral streptomycin (5 mg/ml in drinking water) for 24 h
before oral challenge with  108 CFU of a streptomycin-resis-
tant derivative of E. coli DH5  (DH5 SR) carrying pK184,
pK184subAB, or pK184subAA271B, suspended in 60  l of 20% su-
crose and 10% NaHCO3. Drinking water was supplemented with
5 mg/ml streptomycin and 100  g/ml kanamycin. Mice were
weighed daily, and numbers of the recombinant bacteria in fecal
samples from each group were monitored by plating on LB agar
supplemented with 50  g/ml streptomycin and 50  g/ml kana-
mycin. Alternatively, pairs of BALB/C mice were injected intra-
peritoneally with either 25  g, 5  g, 1  g, or 200 ng purified
SubAB in 0.1 ml PBS.
Anti-SubAB ELISA Assay.  Antibodies to SubAB were mea-
sured by ELISA using 96-well Costar PVC plates that were
coated overnight at 4 C with 100  l of 5  g/ml of purified
SubAB in TBS (25 mM Tris-HCl, 132 mM NaCl, pH 7.5).
Plates were washed with TBS-0.1% Triton X-100 and blocked
with TBS-0.05% Tween-20, 0.02% BSA (TBS-Tween-BSA) for
2 h at 37 C. Plates were washed again and incubated for 4 h at
37 C with 100  l of serial dilutions of mouse serum in TBS-
Tween-BSA, commencing at 1:50. Plates were washed, incu-
bated with goat anti–mouse IgG alkaline phosphatase conjugate
(EIA grade; Bio-Rad Laboratories), and diluted 1:15,000 in TBS-
Tween-BSA for 2 h at 37 C. Plates were washed and developed
with 1 mg/ml p-nitrophenyl phosphate substrate (in 12.5 mM
triethanolamine, 135 mM NaCl, 0.02% BSA, 1 mM MgCl2, 2.5
 M ZnCl2, pH 9.6) for 2 h at 37 C, after which Absorbance at
450 nm was determined. Absorbance above background was
plotted against serum dilution, and the ELISA titer was defined as
the reciprocal of the serum dilution resulting in an A450 reading of
0.2 above background.Paton et al. 39
Results
Initial Detection of the Novel Cytotoxin.  Initially, we dis-
covered the new toxin by testing fresh culture supernatant
of the O113:H21 STEC strain 98NK2 for residual cyto-
toxicity on Vero cells, after absorption with a recombinant
E. coli strain that binds and neutralizes all members of the
Stx family with high avidity. The latter construct expresses
a modified LPS, which mimics the Stx receptor (globotri-
aosyl ceramide; Gb3; reference 7). The absorbed 98NK2
supernatant exhibited significant residual cytotoxicity, with
a titer of  1,280 50% cytotoxic doses (CD50) per milliliter,
compared with 10,240 CD50/ml for unabsorbed superna-
tant. A similar degree of residual cytotoxicity was also ob-
served in supernatant from a derivative of 98NK2 with a
deletion mutation in its single Stx-encoding gene (13).
The cytopathic effect was maximal after 3 d of incubation
and was characterized by rounding of cells, detachment
from the substratum, and loss of viability (judged by Try-
pan blue exclusion).
Characterization of the Novel Cytotoxin Operon.  To iso-
late the novel cytotoxin genes, we tested culture superna-
tants from a 98NK2 cosmid gene bank previously con-
structed in E. coli DH1 (14) for Vero cytotoxicity. Two
cosmid clones with partially overlapping inserts were cyto-
toxic (titers were  1,280 CD50/ml). The inserts of these
cosmids do not contain stx genes, and are derived from a
36.8-kb portion of the 98NK2 megaplasmid pO113, the
sequence of which has been deposited in GenBank/
EMBL/DDBJ (accession no. AF399919.3). The organiza-
tion of genes within the region from nt 5,000 to 17,000 in
this sequence is represented in Fig. 1. Within this region,
there are two closely linked genes that we have designated
subA and subB. The subA gene is located on the comple-
mentary strand (nt 13,725–14,768 of AF399919.3) and is
preceded by a ribosome binding site (GGAGGAG; nt
14,772–14,778). A putative promoter sequence was identi-
fied using the NNPP program (15) with transcription pre-
dicted to start at nt 14,831. The subA gene encodes a 347–
amino acid (aa) putative secreted protein with a modest
degree of similarity to members of the Peptidase_S8 (sub-
tilase) family of serine proteases (pfam00082.8). Its closest
bacterial relative is the BA_2875 gene product of Bacillus
anthracis (26% identity, 39% similarity over 246 aa). The
deduced aa sequence includes a predicted signal peptide
cleavage site (determined using the program SignalP V1.1;
reference 16) between A21 and E22, which was subse-
quently confirmed by NH2-terminal aa sequence analysis of
isolated protein. PROSITE analysis also indicated that
SubA contains three conserved sequence domains, desig-
nated the catalytic triad, characteristic of members of the
subtilase family (17). The SubA domain sequences match
the consensus sequences for the so-called Asp, His, and Ser
subtilase catalytic domains at 11/12, 10/11, and 10/11 po-
sitions, respectively, including the known active site resi-
dues (Fig. 2).
The subB gene is 16 nt downstream of subA (nt 13,283–
13,708 of AF399919.3) and is preceded by a ribosome-
binding site (GGAGG; nt 13,714–13,718). An additional
putative promoter sequence was identified upstream of
subB with transcription predicted to start at nt 13,774. A
potential stem-loop element ( G    19.6 kcal/mol) lo-
cated immediately downstream of subB (nt 13,176–13,206)
may function as a transcription terminator for both subA
and subB because no such elements were identified down-
stream of subA. The subB gene encodes a 141-aa protein
with significant similarities to putative exported proteins
from Yersinia pestis (YPO0337; 56% identity, 79% similarity
over 136 aa) and Salmonella typhi (STY1891; 50% identity,
68% similarity over 117 aa). STY1891 has similarity (30%
identity over 101 aa) to the S2 subunit of Ptx, but there is
negligible similarity between SubB and the latter. Like
SubA, the deduced aa sequence of SubB includes a pre-
dicted signal peptide cleavage site between A23 and E24,
which was also confirmed by NH2-terminal analysis.
Requirement of Both subA and subB for Cytotoxicity.  To
examine the cytotoxicity of their products, we amplified
subA, subB, or both subA and subB (subAB) by PCR, sub-
cloned them into pK184, and transformed them into E. coli
JM109. Culture supernatant of JM109:pK184subAB was
Figure 1. Map of part of the megaplasmid pO113
from 98NK2. (top) The scale indicates the correspond-
ing nt numbers in AF399919.3. The locations of the
subA and subB ORFs are shown in black arrows; other
ORFs are indicated by white arrows. The gray boxes
represent incomplete IS3-like elements. The locations
of putative promoters (P) and transcription terminator
sequences (t) are also indicated.
Figure 2. Alignment of the three putative catalytic domains of SubA
with the consensus sequence for Asp, His, and Ser catalytic domains of
members of the subtilase family (reference 17). The numbers above the
SubA fragments indicate the residue number of the terminal aas. Alterna-
tive consensus residues at a given position are shown vertically. The
known active site residues in each subtilase catalytic domain (reference
17) are shown in bold type and underlined. *, SubA residues that do not
match the consensus sequence.E. coli Subtilase Cytotoxin 40
strongly cytotoxic for Vero cells ( 40,960 CD50/ml). As
observed with Stx-absorbed 98NK2 culture supernatant,
the cytopathic effect was maximal after 3 d of incubation
and was characterized by rounding of cells, detachment
from the substratum, and loss of viability (Fig. 3).
However, culture supernatants of JM109:pK184subA and
JM109:pK184subB were not cytotoxic ( 10 CD50/ml).
Western blot analysis of the supernatants using polyclonal
murine antisera raised against purified SubA or SubB con-
firmed that the appropriate clones produced immunoreac-
tive species of the expected sizes (35 and 13 kD for SubA
and SubB, respectively; Fig. 4). Cell lysates of the clones
were also tested on Vero cells, and that of JM109:
pK184subAB was at least 10 times more cytotoxic than the
respective culture supernatant, which is consistent with
poor release of secreted proteins from the periplasm of E.
coli K-12 strains. CHO and Hct-8 cells were also suscepti-
ble to the JM109:pK184subAB culture supernatant, albeit
to a lesser extent (toxin titers were 2,000 and 250 CD50/
ml, respectively). CHO cells are known to be refractory to
Stx (18), whereas Hct-8 cells are sensitive (19).
The requirement for both subA and subB for cytotoxicity
was confirmed by constructing nonpolar subA and subB de-
letion mutants of STEC 98NK2. Replacement of nt 169–
908 of the subA coding sequence or nt 83–352 of the subB
coding sequence with a 1.6-kb kanamycin resistance
cassette was confirmed by PCR and sequence analysis.
The resulting mutants were designated 98NK2 subA and
98NK2 subB, respectively. Western blot analysis con-
firmed that the former produced SubB, but not SubA,
whereas the latter mutant produced SubA, but not SubB,
as expected (unpublished data). The cytotoxicity of cul-
ture supernatants and cell lysates of 98NK2 subA and
98NK2 subB were examined using CHO cells, which as
aforementioned, are susceptible to SubAB, but refractory
to the effects of Stx. Unlike the wild-type 98NK2 extracts,
those from either of the mutants had undetectable cytotox-
icity. Thus, cytotoxicity requires the presence of both subA
and subB.
To determine whether polyclonal murine anti-SubA or
anti-SubB were capable of neutralizing toxin activity, serial
dilutions of toxin were preincubated with 10- l volumes
of serum at 37 C for 30 min and assayed for residual cyto-
toxicity on Vero cells. No neutralization was detected us-
ing nonimmune mouse serum, but anti-SubA and anti-
SubB neutralized 6,400 and 3,200 CD50 of toxin per ml,
respectively (unpublished data).
Site-directed Mutagenesis of SubA.  To determine the ex-
tent to which the cytotoxicity of SubAB was dependent on
its putative subtilase activity, we constructed a derivative of
JM109:pK184subAB with a point mutation such that the
predicted active site serine residue (S271) in SubA was al-
tered to alanine. Culture supernatant from this derivative
(designated JM109:pK184subAA271B) contained both anti-
SubA– and anti-SubB–reactive species of 35 and 13 kD, re-
Figure 3. Cytotoxicity of SubAB for Vero cells. Monolayers were
treated with 1:80 dilutions of culture supernatant from the indicated
strains for 72 h and photographed under phase-contrast microscopy.
Figure 4. Western blot analysis of subclones. Culture lysates of E. coli
JM109 carrying the indicated plasmids were separated by SDS-PAGE,
electroblotted onto nitrocellulose, and probed with anti-SubA (top) or
anti-SubB (bottom). The Marker track contains BenchMark prestained
protein markers (Invitrogen), and the approximate sizes of visible bands
are indicated on the left side of the figure. The approximate sizes of the
immunoreactive species are also indicated on the right.Paton et al. 41
spectively (Fig. 4). However, supernatant and cell lysate
fractions from this clone exhibited markedly reduced cyto-
toxicity for Vero cells, with titers of 40 and 320 CD50/ml,
respectively (Fig. 3). Thus, the point mutation reduced
specific cytotoxicity by  99.9%. Therefore, we have named
the new toxin “Subtilase cytotoxin.”
Transcriptional Analysis.  We assessed transcription of
subA and subB in 98NK2 and JM109:pK184subAB by real-
time RT-PCR using primer pairs that direct amplification
of  230-bp fragments within subA, within subB, or span-
ning  subA and subB. RNA templates from both strains
yielded similar quantities of RT-PCR product with all
three primer sets (unpublished data). This indicates that the
subA and subB ORFs are cotranscribed.
Purification of the SubAB Holotoxin.  The aforemen-
tioned clear requirement for both SubA and SubB for cy-
totoxicity strongly suggests that the two proteins function
together. To examine whether they form an active com-
plex (i.e., an ABn holotoxin), we subcloned a DNA frag-
ment containing the complete subAB region into the ex-
pression vector pET-23( ) such that a His6 tag was fused
to the COOH terminus of the expressed SubB protein.
We subjected lysates of E. coli Tuner™(DE3) expressing
this construct to Ni-NTA affinity chromatography. Pro-
teins were eluted from the column with a 0–500-mM imi-
dazole gradient, and fractions were analyzed by SDS-
PAGE and Coomassie blue staining, as well as by Western
blot using polyclonal anti-SubA or monoclonal antibody
to the His6 tag (Fig. 5). The earlier fractions (nos. 3 and
4) contained multiple protein species, including small
amounts of anti-SubA–reactive material. However, all the
later fractions (references 6–8 and unpublished data) con-
tained only two protein species with sizes of 35 and 14 kD,
as predicted for SubA and SubB, respectively (allowing for
the extra His6 at the SubB COOH terminus). These spe-
cies reacted strongly with anti-SubA and anti-His6, respec-
tively. Examination of the Coomassie blue–stained SDS-
PAGE gel indicated that the SubA and SubB species were
present in apparently constant proportions in each of the
fractions ( 1:5 on a molar basis, as judged by densitome-
try). However, the purified SubAB migrated as a single
species when subjected to PAGE under nondenaturing
conditions, and was not dissociated by treatment with 5%
2-mercaptoethanol (unpublished data). Further confirma-
tion of the stoichiometry of the association between SubA
and SubB was obtained by subjecting purified SubAB to
mild cross-linking conditions before SDS-PAGE analysis,
which indicated that the holotoxin has a molecular size of
 105 kD (unpublished data). Collectively, these data indi-
cate that SubA and SubB form a stable complex under
nondenaturing conditions, at a ratio of 1:5.
Cytotoxicity of Purified SubAB.  Purified SubAB was
highly toxic for Vero cells, with a specific activity  1010
CD50/mg. That is,  0.1 pg of SubAB is sufficient to kill at
least 50% of the  3   104 Vero cells present in a microtiter
plate well. For comparison, the specific Vero cell cytotoxic-
ities reported for both major Stx types (Stx1 and Stx2) are in
the range of 1–10 pg/CD50 (20–24). Heating SubAB at
56 C for 30 min had no impact on in vitro cytotoxicity, but
exposure to 75 C for 30 min resulted in  75% inactivation
(unpublished data). This degree of heat stability is similar to
that reported for Stx2 (20). Like the aforementioned crude
extracts tested, SubAB cytotoxicity was maximal after 72 h
incubation of toxin-treated Vero monolayers, and there was
little evidence of a cytopathic effect at 24 h, even at high
toxin doses. Interestingly, however, if Vero cells were
treated with  1,000 CD50/ml of SubAB for 60 min, fol-
lowed by removal of the medium, washing of the monolay-
ers three times with fresh medium, and continuation of in-
cubation in fresh medium, significant cytotoxicity was still
evident 48–72 h later. This suggests that significant amounts
of SubAB were already either tightly bound to the Vero cell
surface, or had entered the cells within the first hour.
We examined entry of SubAB into Vero cells directly,
by immunofluorescence microscopy (Fig. 6). After 48-h
Figure 5. Copurification of SubA and SubB. Crude lysate of E. coli
Tuner™(DE3):pET-23( )subAB was applied to a Ni-NTA column,
washed, and eluted with a linear 0–500-mM imidazole gradient. 10  l
aliquots of the original lysate (lane 1) and fractions 3–9 (lanes 2–8) were
separated by SDS-PAGE and stained with Coomassie blue (A). Lane M
contains SDS-PAGE molecular weight standards (BioRad Laboratories),
and the approximate sizes are indicated on the left of the figure. Alterna-
tively, proteins were electroblotted onto nitrocellulose and probed with
polyclonal anti-SubA (B) or monoclonal anti-His6 (C). Lane M contains
BenchMark prestained protein markers (Invitrogen), and the approximate
sizes of visible bands are indicated on the left side of the figure.E. coli Subtilase Cytotoxin 42
exposure of Vero cells to 1  g/ml of purified SubAB, both
anti-SubA– and anti-SubB–reactive material was clearly ev-
ident within the cytoplasm. No significant labeling was seen
in toxin-treated cells after staining with nonimmune mouse
serum, or in nontoxin-treated cells stained with the specific
antisera. Furthermore, if SubAB-treated cells were not per-
meabilized before staining, very little immunoreactive ma-
terial was observed. Thus, most of the detectable SubAB
appeared to be inside the Vero cells, rather than bound to
the outer surface (Fig. 6). Alternately, when toxin-treated
cells were examined by immunofluorescence after only 1 h,
significant staining of toxin-treated Vero cells was observed
using anti-SubA or anti-SubB, regardless of whether the
cells were permeabilized or not, suggesting that much of
the toxin was bound to the outer surface. No labeling was
observed using nonimmune mouse serum, or if Vero cells
were incubated without toxin (unpublished data).
Neutralization of SubAB by a Receptor Mimic Probiotic.
The B pentamers of previously characterized AB5 toxins are
known to recognize specific oligosaccharide moieties dis-
played by host cell glycolipids (1). Differences in receptor
specificity of the toxins, as well as in the distribution of the
target glycolipids between host species and tissues, has a ma-
jor impact on host susceptibility and tissue tropism, and the
pathology and clinical manifestations of toxin-mediated dis-
ease (25). In an attempt to identify candidate glycolipid re-
ceptors for SubAB, we absorbed toxin extracts with suspen-
sions of recombinant E. coli strains expressing mimics of the
oligosaccharide components of glycolipids Gb3, Gb4, lacto-
neotetraosyl ceramide, and GM2 (references 7, 8 and un-
published data). We tested the absorbed extracts for Vero
cytotoxicity. No detectable neutralization of cytotoxicity
was observed after absorption with any of the first three
constructs, or with the host E. coli strain used to express the
oligosaccharides. However, absorption with the GM2
mimic neutralized 93.4% of the SubAB activity. Thus,
the oligosaccharide expressed by this strain (GalNAc 
[1→4]{NeuAc [2→3]}Gal [1→4]Glc  ) may be a func-
Figure 6. Immunofluorescent analysis. Vero cells were treated with
purified SubAB for 48 h, fixed, permeabilized (except where indicated),
and stained with mouse anti-SubA, anti-SubB, or nonimmune serum,
followed by goat anti–mouse IgG-ALX488 conjugate. (A and C) Anti-
SubA; (B and D) anti-SubB; (E) anti-SubA (nonpermeabilized); (F) anti-
SubB (nonpermeabilized); (G) nonimmune serum; (H) nonimmune serum
(nonpermeabilized); (I) anti-SubA without SubAB treatment; and (J)
anti-SubB without SubAB treatment.
Figure 7. Histological examination of SubAB-treated mice. Mice were
injected intraperitoneally with or without 1  g of purified SubAB. After
6 d, the moribund toxin-treated mouse and the healthy control mouse
were killed; brain, liver, and kidneys were removed; and fixed sections
were examined histologically after staining with hematoxylin and eosin
using a 40  objective. (A) Cerebellar cortex, showing hemolytic
thrombi in molecular and granular layers from the toxin-treated mouse
(arrows). (B) Choroid plexus, showing necrotic toxin-treated epithelial
cells (arrow). (C) Renal cortex, showing interstitial thrombi (arrow), tubular
necrosis (white arrow), and glomerular hyperemia (arrowhead) in the
toxin-treated mouse. (D) Liver parenchyma, showing thrombi (arrow)
and generalized hepatocyte necrosis in toxin-treated mouse.Paton et al. 43
tional receptor for SubAB. To examine whether Vero cells
contain GM2, gangliosides were extracted and analyzed by
thin layer chromatography. The extract contained at least
eight species, as judged by staining with resorcinol, one of
which comigrated with a commercial GM2 standard (un-
published data).
In Vivo Studies.  The in vivo toxicity of SubAB was
examined by intraperitoneal injection of pairs of mice with
25  g, 5  g, 1  g, or 200 ng of purified toxin. All of the
mice died and their survival times were inversely related to
dose levels, ranging from 2 d at 25  g to 8–10 d at 200 ng.
Death was preceded by ataxia and hind limb paralysis, sug-
gestive of neurological involvement. Histological examina-
tion of organs removed from a moribund toxin-treated
mouse revealed extensive microvascular thrombosis and
necrosis in the brain, liver, and kidneys (Fig. 7). One out of
two mice injected with 1  g of partially heat-inactivated
(75 C for 30 min) SubAB died after 8 d, whereas the other
was alive and well at 14 d.
We also challenged groups of streptomycin-treated mice
orally with E. coli DH5  derivatives carrying pK184,
pK184subAB, or pK184subAA271B. The drinking water was
supplemented with streptomycin and kanamycin to inhibit
endogenous gut flora and to select for plasmid mainte-
nance. Each of the constructs was maintained at levels of
 108–109 CFU/g of feces throughout the experiment.
During this period, none of the mice exhibited any ob-
vious diarrhea. The mice challenged with the control
strain DH5 :pK184 or DH5 :pK184subAA271B remained
healthy and active, and gained weight steadily. By day 6,
mice in these groups had gained 1.71   0.21 and 1.98  
0.18 g, respectively. However, the mice colonized with
DH5 :pK184subAB appeared ill and lethargic, and steadily
lost body weight during the first 6 d after challenge. By day
6, they had lost 2.78   0.41 g of body weight (Fig. 8 A),
which is equivalent to 15.7% of their mean starting weight
on day 0 (17.7 g). Even on day 3, the difference in weight
gain between mice challenged with DH5 :pK184subAB
and the other two groups was highly significant (P   0.01;
Student’s t test). The severe weight loss experienced by the
group challenged with the active SubAB-producing clone
indicates that toxin delivered via the gut has significant del-
eterious effects on the host. Moreover, the fact that the
growth of mice challenged with the clone expressing the
SubAB protein with the mutation in the active site Ser res-
idue was indistinguishable from that of mice challenged
with DH5 :pK184 unequivocally attributes the weight loss
to subtilase-mediated cytotoxic activity. Interestingly, the
mice challenged with DH5 :pK184subAB started to gain
weight from day 7, although they lagged significantly be-
hind the other two groups for the entire duration of the
experiment (P   0.001; Fig. 8). To determine whether se-
roconversion could account for this apparent recovery, sera
collected from each of the mice on day 15 were tested for
antibodies to SubAB by ELISA. Only one of the mice
challenged with DH5 :pK184 had detectable anti-SubAB
levels, and this was at the lower limit of detection (titer  
50). However, seven out of eight mice challenged with
DH5 :pK184subAB and five out of eight mice challenged
with DH5 :pK184subAA271B seroconverted; the highest ti-
ters for these groups were 3,100 and 720, respectively (Fig.
8 B). One out of two mice injected intraperitoneally with 1
 g of purified SubAB that had been preincubated for 1 h at
37 C with 100  l of convalescent serum from one of the
mice challenged with DH5 :pK184subAB died after 8 d,
whereas the other was alive and well at 14 d. Preincubation
of toxin with normal mouse serum had no such protective
effect, with death occurring at 4 d (unpublished data).
Distribution of subAB in Other STEC Strains.  The dis-
tribution of subAB-related sequences in other STEC strains
isolated from patients with HUS and/or diarrheal disease,
or from contaminated food linked to an outbreak of HUS,
was investigated by PCR and Southern hybridization anal-
Figure 8. Oral challenge of mice with SubAB-producing clones.
Groups of streptomycin-treated BALB/C mice were fed  108 CFU of E.
coli DH5 SR carrying pK184 (circles), pK184subAB (squares), or
pK184subAA271B (triangles). Drinking water was supplemented with 5
mg/ml streptomycin and 100  g/ml kanamycin. (A) Effect on body
weight. Individually identified mice were weighed on day 0 and daily
from day 3. Data are mean weight gain (  SE), relative to weight of the
respective mouse on day 0. The mean weights of mice in the three groups
on day 0 were 18.7, 17.8, and 18.0 g, respectively. (B) Serum anti-SubAB
levels. Sera collected on day 15 were assayed for antibodies to SubAB by
ELISA. The minimum detectable titer was 50, and sera below this level
have been assigned a nominal titer of 25.E. coli Subtilase Cytotoxin 44
ysis (Table III). The genes are not present in the two pub-
lished O157:H7 STEC genome sequences (26, 27). How-
ever, subAB sequences were present in 32 out of 68 other
STEC strains tested, including representatives of serogroups
O23, O48, O82, O91, O111, O113, O123, O128, O157,
OX3, and O nontypable strains. The subAB probe-reactive
strains included O111:H  and O157:H  isolates linked to a
large outbreak of HUS (28), and lysates of these strains
were cytotoxic for (Stx resistant) CHO cells (unpublished
data). The subAB hybridization signal obtained for the
O111:H  and O157:H  isolates was not as strong as that
seen for the other subAB-reactive strains, suggesting the
possibility of sequence differences (unpublished data). All of
the  subAB positive STEC strains were also positive by
PCR for the STEC enterohemolysin gene ehxA, which is
commonly used as a marker for the presence of an STEC
megaplasmid (unpublished data). The presence of subAB in
diverse clinical isolates may be a consequence of the fact
that at least in 98NK2, the operon is located on a mega-
plasmid (pO113) that is capable of conjugative transmission
(29). However, STEC megaplasmids are heterogeneous
and several of the subAB positive strains tested in this work
have been previously shown to lack the pilS gene, which
facilitates such transfer (29).
Discussion
In the present work, we have characterized a novel Sub-
tilase cytotoxin at both the gene and protein level. SubAB
clearly belongs in a separate family to the other AB5 toxins
characterized to date, as it has distinct A subunit enzymic
activity (subtilase rather than RNA-N-glycosidase or ADP-
ribosylase). Moreover, we have demonstrated that the po-
tent cytotoxicity and deleterious in vivo effects of SubAB
are a consequence of this subtilase activity. The subtilases
are a family of serine proteases found in a wide variety of
microorganisms (17, 30), but to date, no other members
have been shown to have cytotoxic activity. In the present
work, we also exposed Vero monolayers to 1  g/ml puri-
fied Subtilisin Carlsberg (a prototype subtilase from Bacillus
licheniformis; Sigma-Aldrich) and observed no cytotoxic ef-
fect whatsoever (unpublished data). SubA did not appear to
have broad-spectrum proteolytic activity and was unable to
cleave substrates such as collagen or fibronectin, which
might have accounted for the detachment of tissue culture
cells from the substratum (unpublished data). Collagen
cleavage was assessed colorimetrically using dye-linked hide
powder substrate, or by electrophoresis in gelatin-impreg-
nated nondenaturing PAGE gels. Capacity to digest fi-
bronectin was assessed by coincubation of purified human
fibronectin with SubAB followed by analysis by SDS-
PAGE. Immunofluorescence microscopy demonstrated that
SubA and SubB bound to the surface of Vero cells within
1 h and, at 48 h, were detectable inside toxin-treated cells,
but the intracellular substrate of SubA is still unknown.
Nevertheless, the substrate is clearly essential for cell sur-
vival, and elucidation of this target may enable SubAB, like
Ptx, to be used as a tool in cell biology.
The presence of SubB was essential for cytotoxicity, and
it is likely that it is required for recognition and/or entry of
target cells. The neutralization of SubAB activity achieved
by treatment with the GM2 mimic probiotic suggests that
this ganglioside (or one displaying a closely related oli-
gosaccharide) may be a functional receptor for the toxin.
To confirm this specificity, we attempted to neutralize
SubAB with micelles of GM2 purified from bovine brain,
but without success. However, the conformation of oli-
gosaccharide moieties displayed by glycolipids in biological
membranes is also heavily influenced by their own lipid
component, as well as by other lipids present. This has a
major impact on their capacity to interact with binding
sites on AB5 toxins (31), and purified glycolipids generally
exhibit weak binding when presented in micelle form.
The evolutionary origin of Subtilase cytotoxin is unclear,
but the data presented here demonstrate the potentially dire
consequences that might arise from genetic rearrangements
that bring seemingly innocuous genes such as subA and
subB into juxtaposition. The closest bacterial homologue of
SubA is BA_2875 from B. anthracis, but examination of the
genome sequence of the latter did not reveal the presence
of a gene encoding a homologue of SubB in the immediate
vicinity. To our knowledge, there is also no precedent in
the literature for members of the subtilase family of pro-
teases forming stable associations with heterologous poly-
peptides that impact on biological activity (17, 30). Exami-
nation of the Y. pestis and S. typhi genome sequences also
Table III. Distribution of subAB in Other STEC Serogroups
Serogroup No. tested No. subAB a
O23 1 1
O26 3 0
O48 1 1
O82 1 1
O91 2 1
O98 1 0
O111 17 6
O113 5 5
O123 1 1
O128 1 1
O141 1 0
O157 15 3
O159 1 0
OX3 6 5
O nontypable 4 2
O unknown 8 5
Total 68 32
aDetermined by PCR or Southern hybridization (see Materials and
Methods).Paton et al. 45
did not reveal the presence of subA-like genes in the vicin-
ity of their respective subB homologues, both of which en-
code products of unknown function. Nevertheless, the
degree of similarity between these proteins and SubB is
substantial (56% identity and 79% similarity over 136 aa in
the case of Y. pestis YPO0337), and this raises the possibil-
ity that they are structurally and functionally related. Given
the impact of plague and typhoid on human health, it
would be of considerable interest to determine whether
these SubB homologues can (a) form pentamers capable of
binding to eukaryotic cells, and (b) interact with heterolo-
gous proteins produced by the respective organism.
The production of two distinct and highly potent AB5
toxins (Subtilase cytotoxin and Stx) by a bacterium respon-
sible for life-threatening human disease is an important
finding that raises the possibility that both contribute (per-
haps synergistically) to pathogenesis in some cases of STEC
disease. Typically, the relative contributions of virulence
factors can be dissected by examination of the behavior of
toxin mutants in an animal model. However, existing ani-
mal models do not mimic all of the features of STEC dis-
ease in humans. Interspecies and age-related differences in
receptor distribution have a major impact on host suscepti-
bility, tissue tropism, and the resultant pathology generated
by a toxin. Nevertheless, the presence of microvascular
thrombi in the brain and other organs, including the renal
tubules and glomeruli, of a Subtilase cytotoxin–treated
mouse is suggestive of endothelial injury, and is reminiscent
of the pathology seen in cases of HUS in humans. This
finding is particularly intriguing in the light of the report of
strains of E. coli O157:H7 and O157:H  (common STEC
serotypes) that do not produce Stx, being associated with
HUS (4).
The presence of subAB in diverse STEC isolates from
cases of severe human disease demands rigorous investiga-
tion of the toxin’s biological effects in vitro and in vivo.
The fact that subAB is carried on a mobile DNA element
and its presence in a diverse range of E. coli O serogroups
also raises the possibility of further transmission to other
enteric bacteria. If an unequivocal role for Subtilase cyto-
toxin in disease in humans or animals becomes apparent,
the work presented here will provide the foundation for ef-
fective diagnostic, therapeutic, and preventative strategies.
We have reported PCR primers suitable for use in direct
detection of subAB-carrying bacteria in complex clinical
and environmental samples. We have demonstrated that a
Ser271-Ala substitution in SubA virtually abolishes cytotox-
icity of SubAB, and that expression of this protein in the
GI tract of mice has no adverse consequences, yet elicits a
serum antibody response. Thus, we have identified a safe
candidate vaccine antigen. Finally, by demonstrating that a
harmless strain of E. coli expressing a mimic of the oligosac-
charide component of ganglioside GM2 neutralizes SubAB,
we have identified a means of absorbing Subtilase cytotoxin
in the gut of infected individuals. Previously, we have
demonstrated the in vivo efficacy of this receptor-mimic
therapeutic strategy using a mimic of the Stx receptor (7).
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